Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced new dermatology data ...

Biocon Biologics presents dermatology data at EADV 2024 Congress, showcasing interchangeability and biosimilarity of ...

Two Phase 3 studies have demonstrated that patients can safely switch between adalimumab, a well-known biologic therapy, and ...

Biocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its ...

Biocon Biologics presents new dermatology data from two clinical studies at EADV Congress 2024: Our Bureau, Bengaluru Wednesday, September 25, 2024, 13:40 Hrs [IST] Biocon Biologi ...

Bangalore: Biocon has announced that the U.S. Food and Drug Administration (US FDA) has concluded a surveillance inspection ...

Sensex ended the day with the gain of 256 points to 85,169 and Nifty surged 63 points to 26,004 on. Nifty Bank zoomed 133 ...

Temasek Holdings Pte is nearing a deal to acquire a significant minority stake in VFS Global, valuing the visa outsourcing firm at ..... Biocon Ltd is looking to raise fresh funding for its ...

The biotechnology industry hopes the new Vigyan Dhara initiative of the Union government with a Rs. 10,000 crore outlay will result in better fund utilisation, and improve efficiency with its support ...

BENGALURU, India, Aug. 29, 2024 /CNW/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today ...

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has secured market entry for its proposed biosimilar to Stelara in Europe, the UK, Canada, and Japan. The company announced today ...